Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH) with a stabilizing N-terminal hexenoyl modification that resists enzymatic degradation. It is the only GHRH-analog peptide approved by the FDA for any indication, originally for HIV-associated lipodystrophy under the brand name Egrifta. Documented research spans GH/IGF-1 axis stimulation, visceral adipose tissue biology, hepatic fat metabolism, and lipid profile modulation.
Ipamorelin is a synthetic pentapeptide developed in the late 1990s as a selective growth hormone secretagogue in the GHRP family. It binds the ghrelin receptor (GHSR1a) to stimulate pulsatile GH release without significant cortisol or prolactin elevation observed with earlier-generation secretagogues. Documented research spans pulsatile GH release pharmacology, longitudinal bone growth in animal models, and counteraction of glucocorticoid-induced bone loss.
The combination is a classical research-stack pairing: a GHRH analog (Tesamorelin) plus a GHRP-family secretagogue (Ipamorelin), each acting on a different point of the somatotrophic axis. Neither compound has been approved by the FDA for human use outside the original GHRH-research and HIV-associated lipodystrophy context. Both remain classified as research compounds outside that approved indication.
For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA in this formulation.
